Labiotech.eu

News and Trends 24 Aug 2022

Gene therapies for lung cancer identified by international team of scientists

Gene therapies for lung cancer can be found by CRISPR genome editing technology, an international team of scientists have discovered. CRISPR genome-editing is a powerful tool that gives scientists a cheap and easy way to find and alter a specific piece of DNA within a cell – the ‘cut and paste’ of the biological world. […]

August 24, 2022 - 2 minutesmins - By Liza Laws

News and Trends 24 Aug 2022

Study findings could lead to new anti-cancer drugs

German scientists say a drug already approved for other purposes can negate how tumor cells protect themselves from the immune system. Many tumor cells mist themselves with a protective ‘perfume’ that disables the immune system. But a drug already approved for other purposes can apparently render this weapon harmless. This is the conclusion of a […]

August 24, 2022 - 4 minutesmins - By Jim Cornall

Optics11 Life receives €5 million in funding for drug development

News and Trends 24 Aug 2022

Millions in funding and new board members for Belgian mRNA company

The mRNA technologies company eTheRNA has raised €39 million ($38.7 million) in series B2 financing. Belgium-based eTheRNA will use the money to expand investment in its integrated mRNA technology platform and further pursue its new initiatives for a partnership-driven business strategy. The round was led by Novalis LifeSciences LLC with participation from Professor Kenneth Chien, […]

August 24, 2022 - 3 minutesmins - By Liza Laws

covid-19 vaccine emergency use authorization

More News! 24 Aug 2022

COVID-19 vaccine less sensitive to mutations being developed in Sweden

A new generation of coronavirus vaccine is being developed by Swedish researchers from the Karolinska Institutet. The vaccine is being specifically designed to be less sensitive to mutations and better equipped for any future strains. Promising results The vaccine showed promising results in mice in a newly published study in EMBO Molecular Medicine, and the researchers […]

August 24, 2022 - 3 minutesmins - By Liza Laws

News and Trends 24 Aug 2022

Potential new treatment for angioimmunoblastic T-cell lymphoma?

A type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from which the T cells in the blood develop. However, the underlying mechanism by which AITL develops was unknown. Now, a team from the University of Tsukuba in Japan have shown that B […]

August 24, 2022 - 3 minutesmins - By Jim Cornall

In Depth 24 Aug 2022

To reach Mars, we need biotechnology

As we prepare for long-distance space travel and life on Mars, biotechnology will be essential to make spaceships no longer dependent on Earth’s constant supply. “As human beings, we need a constant supply of oxygen. We need constant access to nutritious food, clean water and a safe and clean waste disposal system,” says Italian astronaut […]

August 24, 2022 - 11 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Aug 2022

BioAge partners with Age Labs to study healthy life length

BioAge Labs, Inc., a biotech company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, has partnered with Age Labs AS, a diagnostic company that develops tests for the early detection of age-related diseases. Under the terms of the agreement, BioAge will perform multi-omics analyses on samples and health records […]

August 24, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 24 Aug 2022

Oncolyze seeking investment for AML clinical trials

After successfully completing in vitro and in vivo experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer cells and increases survival rates, Oncolyze now has its sights set on advancing OM-301 into clinical trials. Oncolyze has launched a Regulation A+ funding campaign to spread awareness of OM-301 among cancer patients, […]

August 24, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 24 Aug 2022

Amgen announces top-line results from biosimilar phase 3 study

Amgen has announced positive top-line results from its DAHLIA study. This was a randomized, double-blind, active-controlled, two-period crossover phase 3 study evaluating the efficacy and safety of ABP 959, a biosimilar candidate to SOLIRIS (eculizumab), compared with SOLIRIS in adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Amgen said the study met its primary endpoints, demonstrating […]

August 24, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 24 Aug 2022

Northwest Biotherapeutics’ pediatric investigation plan approved by MHRA

Northwest Biotherapeutics, a biotech company developing DCVax personalized immune therapies for solid tumor cancers, has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its pediatric investigation plan (PIP). The development, regulatory review and regulatory approval of a PIP is a pre-requisite for application for approval of a new medicine for […]

August 24, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Freedom Biosciences exits stealth with $10.5M financing to develop mental health treatments

Freedom Biosciences, a U.S. clinical-stage biotech platform developing ketamine and psychedelic therapeutics, today emerged from stealth with $10.5 million in seed financing. MBX Capital led the round and was joined by PsyMed Ventures, Village Global and The Yale Startup, among others. The new financing will help the company advance its current lead ketamine program as […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

Cytimmune Sciences nanoparticles red recognizing entering and accumulating in cancer cells

News and Trends 23 Aug 2022

Novel nanotechnology ‘supercharges’ immune system molecules to fight cancer

Researchers from Cytimmune Sciences, a clinical-stage biotech company, have presented new data on the company’s novel cancer nanomedicines. The presentation took place at the Cytokine Drug Development Conference held in Boston, Massachusetts, late last month. David Oarr, Cytimmune’s president, participated in the event’s opening panel to discuss the current clinical status and future anticipated progress […]

August 23, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Gene therapies for lung cancer identified by international team of scientists

Study findings could lead to new anti-cancer drugs

Millions in funding and new board members for Belgian mRNA company

COVID-19 vaccine less sensitive to mutations being developed in Sweden

Potential new treatment for angioimmunoblastic T-cell lymphoma?

To reach Mars, we need biotechnology

BioAge partners with Age Labs to study healthy life length

Oncolyze seeking investment for AML clinical trials

Amgen announces top-line results from biosimilar phase 3 study

Northwest Biotherapeutics’ pediatric investigation plan approved by MHRA

Freedom Biosciences exits stealth with $10.5M financing to develop mental health treatments

Novel nanotechnology ‘supercharges’ immune system molecules to fight cancer

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!